Manipulated Mesenchymal Stem Cell Therapy in the Treatment of Parkinson's Disease

Overview

Journal Stem Cell Res Ther

Publisher Biomed Central

Date 2024 Dec 19

PMID 39696636

Authors

Seyedeh Toktam Ekrani

Mahmoud Mahmoudi

Dariush Haghmorad

Ramiar Kamal Kheder

Alireza Hatami

Seyed-Alireza Esmaeili

Affiliations

Soon will be listed here.

Abstract

Mesenchymal stem cell (MSC) therapy has been considered a promising approach for the treatment of Parkinson's disease (PD) for several years. PD is a globally prevalent neurodegenerative disease characterized by the accumulation of Lewy bodies and the loss of dopaminergic neurons, leading to severe motor and non-motor complications in patients. As current treatments are unable to halt the progression of neuronal loss and dopamine degradation, MSC therapy has emerged as a highly promising strategy for PD treatment. This promise is due to MSCs' unique properties compared to other types of stem cells, including self-renewal, differentiation potential, immune privilege, secretion of neurotrophic factors, ability to improve damaged tissue, modulation of the immune system, and lack of ethical concerns. MSCs have been employed in numerous pre-clinical and clinical studies for PD treatment with promising results. However, certain aspects of their efficacy in treating PD may benefit from various genetic and epigenetic modifications. In this review article, we assess these approaches to improving MSCs for specialized treatment of PD.

References

Vural A, Odabas S, Korkusuz P, Saglam A, Bilgic E, Cavusoglu T . Cranial bone regeneration via BMP-2 encoding mesenchymal stem cells. Artif Cells Nanomed Biotechnol. 2016; 45(3):544-550. DOI: 10.3109/21691401.2016.1160918. View

de Cassia Noronha N, Mizukami A, Caliari-Oliveira C, Cominal J, Rocha J, Covas D . Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies. Stem Cell Res Ther. 2019; 10(1):131. PMC: 6498654. DOI: 10.1186/s13287-019-1224-y. View

McCoy M, Martinez T, Ruhn K, Wrage P, Keefer E, Botterman B . Autologous transplants of Adipose-Derived Adult Stromal (ADAS) cells afford dopaminergic neuroprotection in a model of Parkinson's disease. Exp Neurol. 2007; 210(1):14-29. PMC: 2394500. DOI: 10.1016/j.expneurol.2007.10.011. View

Bhatti F, Mehmood A, Latief N, Zahra S, Cho H, Khan S . Vitamin E protects rat mesenchymal stem cells against hydrogen peroxide-induced oxidative stress in vitro and improves their therapeutic potential in surgically-induced rat model of osteoarthritis. Osteoarthritis Cartilage. 2016; 25(2):321-331. DOI: 10.1016/j.joca.2016.09.014. View

Li M, Zhang S, Guo Y, Cai Y, Yan Z, Zou Z . Human umbilical vein-derived dopaminergic-like cell transplantation with nerve growth factor ameliorates motor dysfunction in a rat model of Parkinson's disease. Neurochem Res. 2010; 35(10):1522-9. DOI: 10.1007/s11064-010-0211-6. View

Zargarani S, Tavaf M, Soltanmohammadi A, Yazdanpanah E, Baharlou R, Yousefi B . Adipose-derived mesenchymal stem cells ameliorates experimental autoimmune encephalomyelitis via modulation of Th1/Th17 and expansion of Th2/Treg responses. Cell Biol Int. 2024; 48(8):1124-1137. DOI: 10.1002/cbin.12171. View

Miceli V, Zito G, Bulati M, Gallo A, Busa R, Iannolo G . Different priming strategies improve distinct therapeutic capabilities of mesenchymal stromal/stem cells: Potential implications for their clinical use. World J Stem Cells. 2023; 15(5):400-420. PMC: 10277962. DOI: 10.4252/wjsc.v15.i5.400. View

Rosova I, Dao M, Capoccia B, Link D, Nolta J . Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells. Stem Cells. 2008; 26(8):2173-82. PMC: 3017477. DOI: 10.1634/stemcells.2007-1104. View

Hahn J, Cho H, Kang H, Kim T, Kim M, Chung J . Pre-treatment of mesenchymal stem cells with a combination of growth factors enhances gap junction formation, cytoprotective effect on cardiomyocytes, and therapeutic efficacy for myocardial infarction. J Am Coll Cardiol. 2008; 51(9):933-43. DOI: 10.1016/j.jacc.2007.11.040. View

10.

Hosseini S, Mahmoudi M, Rezaieyazdi Z, Shapouri-Moghaddam A, Hosseinzadeh A, Arab F . Lupus mice derived mesenchymal stromal cells: Beneficial or detrimental on SLE disease outcome. Int Immunopharmacol. 2023; 126:111306. DOI: 10.1016/j.intimp.2023.111306. View

11.

Li J, Yin H, Shuboy A, Duan H, Lou J, Li J . Differentiation of hUC-MSC into dopaminergic-like cells after transduction with hepatocyte growth factor. Mol Cell Biochem. 2013; 381(1-2):183-90. DOI: 10.1007/s11010-013-1701-z. View

12.

Schwerk A, Altschuler J, Roch M, Gossen M, Winter C, Berg J . Human adipose-derived mesenchymal stromal cells increase endogenous neurogenesis in the rat subventricular zone acutely after 6-hydroxydopamine lesioning. Cytotherapy. 2014; 17(2):199-214. DOI: 10.1016/j.jcyt.2014.09.005. View

13.

Zhao C, Li H, Zhao X, Liu Z, Zhou P, Liu Y . Heat shock protein 60 affects behavioral improvement in a rat model of Parkinson's disease grafted with human umbilical cord mesenchymal stem cell-derived dopaminergic-like neurons. Neurochem Res. 2016; 41(6):1238-49. DOI: 10.1007/s11064-015-1816-6. View

14.

Huerta C, Ortiz Y, Li Y, Ribieras A, Voza F, Le N . Novel Gene-Modified Mesenchymal Stem Cell Therapy Reverses Impaired Wound Healing in Ischemic Limbs. Ann Surg. 2023; 278(3):383-395. PMC: 10414148. DOI: 10.1097/SLA.0000000000005949. View

15.

Politis M, Lindvall O . Clinical application of stem cell therapy in Parkinson's disease. BMC Med. 2012; 10:1. PMC: 3261810. DOI: 10.1186/1741-7015-10-1. View

16.

Farooqui N, Mohan A, Isik B, Goksu B, Thaler R, Zhu X . Effect of Hypoxia Preconditioning on the Regenerative Capacity of Adipose Tissue Derived Mesenchymal Stem Cells in a Model of Renal Artery Stenosis. Stem Cells. 2022; 41(1):50-63. PMC: 9887092. DOI: 10.1093/stmcls/sxac073. View

17.

Wu J, Yu W, Chen Y, Su Y, Ding Z, Ren H . Intrastriatal transplantation of GDNF-engineered BMSCs and its neuroprotection in lactacystin-induced Parkinsonian rat model. Neurochem Res. 2009; 35(3):495-502. DOI: 10.1007/s11064-009-0086-6. View

18.

Schiess M, Suescun J, Doursout M, Adams C, Green C, Saltarrelli J . Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Safety in Idiopathic Parkinson's Disease. Mov Disord. 2021; 36(8):1825-1834. PMC: 8451899. DOI: 10.1002/mds.28582. View

19.

Herrmann J, Wang Y, Abarbanell A, Weil B, Tan J, Meldrum D . Preconditioning mesenchymal stem cells with transforming growth factor-alpha improves mesenchymal stem cell-mediated cardioprotection. Shock. 2009; 33(1):24-30. DOI: 10.1097/SHK.0b013e3181b7d137. View

20.

Xiong N, Huang J, Chen C, Zhang Z, Jia M, Xiong J . VEGF-expressing human umbilical cord mesenchymal stem cells, an improved therapy strategy for Parkinson's disease. Gene Ther. 2010; 18(4):394-402. DOI: 10.1038/gt.2010.152. View